Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Quest Diagnostics Nichols Institute

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Quest Diagnostics Nichols Institute

Regulatory records
1
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 1 FDA record to the applicant name Quest Diagnostics Nichols Institute. It includes 1 original PMA approval. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Jul 24, 2025 to Jul 24, 2025. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code QWQ appears in 1 of the 1 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P250002, with 1 linked entry. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.

Applicant mailing address recorded by FDA: 33608 Ortega Hwy., San Juan Capistrano, CA, 92675. Recorded on P250002, decision dated Jul 24, 2025.

Changes described in PMA records

P250002: Quest Diagnostics AAVrh74 Antibody ELISA CDx

FDA’s recorded scope: Quest Diagnostics AAVrh74 Antibody ELISA CDx is an enzyme-linked immunosorbent in vitro diagnostic assay intended for the semi-quantitative detection of antibodies (IgG) to AAVrh74 capsid in human serum. The test reports an antibody titer, and a semi-quantitative interpretation of the test results derived from the antibody titer. Patients with an AAVrh74 antibody titer less than 1:400 are reported as not elevated for AAVrh74 antibody titers and may be eligible for treatment with the gene therapy. Patients with an AAVrh74 antibody titer greater than or equal to 1:400 are reported as elevated for AAVrh74 antibody titers and are ineligible for treatment with the gene therapy. The test is for prescription use only. The test is intended to be used in conjunction with other available clinical information as an aid to identify patients eligible for treatment with indicated gene therapies.

Jul 24, 2025

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
Quest Diagnostics Nichols InstitutePMA approvalJul 24, 2025FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 21, 2026.